Citations 1
B cell and aquaporin‐4 antibody relationships with neuromyelitis optica spectrum disorder activity
Bennett, Jeffrey L. , Pittock, Sean J. , Paul, Friedemann , Kim, Ho Jin , Irani, Sarosh R. , O'Connor, Kevin C., Patterson, Kristina R. , Gunsior, Michele , Mittereder, Nanette , Rees, William A. , Cimbora, Daniel , Pittock, S J , Cree, Bruce Ac , Bennett, Jeffrey L , Irani, Sarosh R , Paul, Friedemann , Smith, Michael A. , Cree, Bruce
Annals of Clinical and Translational Neurology | September 2, 2024 | Volume: 11 | Issue: 10 | Pages: 2792-2798
Abstract This post hoc analysis of the randomized, placebo‐controlled N‐MOmentum study (NCT02200770) of inebilizumab in neuromyelitis optica spectrum disorder (NMOSD) evaluated relationships between circulating B‐cell subsets and aquaporin‐4 immunoglobulin G (AQP4‐lgG) titers and attacks. Among participants receiving placebo, CD20 + and CD27 + B‐cell counts were modestly increased from the pre‐attack visit to attack; plasmablast/plasma cell gene signature was increased from baseline to the pre‐attack visit ( p = 0.016) and from baseline to attack ( p = 0.009). With inebilizumab treatment, B‐cell subset counts decreased and did not increase with attacks. No difference in change of AQP4‐IgG titers from baseline to time of attack was observed.